TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody)
may stop the growth of tumor cells by allowing the immune system to attack the cancer. This
phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042
(dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally
advanced or metastatic liver cancer.